Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 3,096 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Active, not recruiting Phase 2 Interventional

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT01880567
View directory record Official record
Conditions
CCND1 Positive, CCND2 Positive, CCND3 Positive, CD20 Positive, Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Rituximab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

Nuclear and Near-Infrared (NIR) Imaging in Melanoma

NCT01295931
View directory record Official record
Conditions
Melanoma
Interventions
Indocyanine Green (IC-Green), Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Not applicable Interventional

Effect of EHealth Coaching Program on Patient Reported Outcomes of Men With Prostate Cancer

NCT04106245
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Behavioral Intervention, Survey Administration
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 24, 2026, 7:05 AM EDT
Completed No phase listed Observational

Quantitative Diffusion and Fat Imaging of the Spine

NCT00498277
View directory record Official record
Conditions
Osteoporosis
Interventions
Magnetic Resonance Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma

NCT00427765
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma
Interventions
Busulfan, Melphalan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 24, 2026, 7:05 AM EDT
Completed No phase listed Observational

Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery

NCT00501319
View directory record Official record
Conditions
Lung Cancer
Interventions
Interactive Voice Response (IVR), Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 24, 2026, 7:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

NCT06383572
View directory record Official record
Conditions
Lymphodepleting Chemotherapy, Myeloid Malignancies
Interventions
Cyclophosphamide, Fludarabine phosphate, Decitabine, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Active, not recruiting Not applicable Interventional

An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer

NCT04871139
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Biopsy, Contrast-Enhanced Mammography, Questionnaire Administration, Radioactive Iodine
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Active, not recruiting No phase listed Observational

Patient Considerations of Social Media Account Management After Death

NCT05035667
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm
Interventions
Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Recruiting No phase listed Observational

A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain

NCT05342454
View directory record Official record
Conditions
Brain Tumor
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Results available

Denosumab for Breast Cancer With Bone Mets

NCT01952054
View directory record Official record
Conditions
Breast Cancer
Interventions
Denosumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Not applicable Interventional

Effects of Yoga in Breast Cancer Patients

NCT00508794
View directory record Official record
Conditions
Breast Cancer
Interventions
Yoga Group, Stretching Control Group, Waitlist Control Group, Questionnaire
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 24, 2026, 7:05 AM EDT
Active, not recruiting Not applicable Interventional

Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer

NCT05132296
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Behavioral Intervention, Best Practice, FitBit, Nutrition Education, Physical Activity, Questionnaire Administration
Behavioral · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Recruiting No phase listed Observational

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT04751396
View directory record Official record
Conditions
Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions
Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Active, not recruiting Not applicable Interventional

Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Brain Tumors

NCT03606161
View directory record Official record
Conditions
Brain Neoplasm
Interventions
Questionnaire Administration, Transcranial Magnetic Stimulation
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

NCT01143779
View directory record Official record
Conditions
Advanced Cancer
Interventions
FLT-PET
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

Lapatinib With Sirolimus or Metformin

NCT01087983
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lapatinib, Sirolimus, Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 24, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

NCT02421354
View directory record Official record
Conditions
Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Splenomegaly
Interventions
Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

NCT01365156
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma, Adenosquamous Carcinoma, Adenocarcinoma, Locally Advanced Malignant Neoplasm, Cervical Cancer
Interventions
Extraperitoneal laparoscopic lymphadenectomy (EPLND), Chemoradiation
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 24, 2026, 7:05 AM EDT
Not yet recruiting Phase 1 Interventional

MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

NCT06549751
View directory record Official record
Conditions
Pancreas Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer (Unresectable)
Interventions
MT-601 dose 200 million cells, MT-601 dose 400 million cells, MT-601 dose 800 million cells, MT-601 dose 1200 million cells
Drug
Lead sponsor
Marker Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Not applicable Interventional

Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy

NCT03868579
View directory record Official record
Conditions
Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm
Interventions
Biopsy, Medical Chart Review, Thoracoscopy
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 24, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional

Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

NCT02225496
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Transoral Robotic Surgery (TORS), Modified Barium Swallow (MBS), Questionnaires
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 24, 2026, 7:05 AM EDT
Recruiting Early Phase 1 Interventional

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

NCT05620342
View directory record Official record
Conditions
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
Interventions
iC9.GD2.CAR.IL-15 T Infusion
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 24, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

NCT04188405
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Decitabine, Ponatinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 24, 2026, 7:05 AM EDT